Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | TTK | P33981 | 3/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007786 | 0.90 | JAK3 (0.54) | JAK3JAK2JAK1TTKTYK2 | |
| SCHEMBL4369271 | 0.88 | CTSC (0.53) | JAK3BTKEGFR | |
| SCHEMBL4334439 | 0.87 | KMT2A (0.46) | JAK3BTKEGFR | |
| SCHEMBL4364555 | 0.86 | JAK3 (0.43) | JAK3JAK2JAK1TTKBTK | |
| SCHEMBL4335022 | 0.86 | BTK (0.42) | JAK3BTKEGFR | |
| SCHEMBL4336930 | 0.86 | LMNA (0.46) | BTKEGFRNTRK1 | |
| SCHEMBL1027584 | 0.85 | MAPT (0.51) | JAK3BTKEGFR | |
| SCHEMBL13623118 | 0.85 | AURKA (0.50) | JAK3JAK2JAK1TTKTYK2 | |
| SCHEMBL1025084 | 0.85 | JAK3 (0.42) | JAK3JAK2JAK1TTKBTK | |
| SCHEMBL1073861 | 0.84 | MAP3K8 (0.46) | EGFRNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | JAK3 4/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.